NFE2L2 and Parkinson disease: Existing evidence points toward melatonin’s role as an antioxidant showing systemic therapeutic benefits in PD-relevant clinical trials (dyskinesia, sleep disorder)187, which combined with amphiphilic nature allowing for BBB diffusion further encourages therapeutic focus revisiting melatonin as a mitophagy agonist with NF-κB and Nrf2 activating effect mentioned prior187.